|
1）Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimerʼs disease: recommendations from the National Institute on Aging-Alzheimerʼs Association workgroups on diagnostic guidelines for Alzheimerʼs disease. Alzheimers Dement. 2011; 7: 280-92
|
|
|
|
2）Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag. 2008; 4: 363-81
|
|
|
|
|
|
3）Knecht S, Wersching H, Lohmann H, et al. High-normal blood pressure is associated with poor cognitive performance. Hypertension. 2008; 51: 663-8
|
|
|
|
|
|
4）Ninomiya T, Ohara T, Hirakawa Y, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension. 2011; 58: 22-8
|
|
|
|
|
|
5）Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005; 4: 487-99
|
|
|
|
|
|
6）Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimerʼs disease prevalence. Lancet Neurol. 2011; 10: 819-28
|
|
|
|
|
|
7）Kerola T, Kettunen R, Nieminen T. The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly? Int J Cardiol. 2011; 150: 123-9
|
|
|
|
|
|
8）Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011; 76: 1485-91
|
|
|
|
|
|
9）Carotenuto A, Rea R, Colucci L, et al. Late and early onset dementia: What is the role of vascular factors? A retrospective study. J Neurol Sci. 2012; 322: 170-5
|
|
|
|
|
|
10）Levi Marpillat N, Macquin-Mavier I, Tropeano AI, et al. Antihypertensive classes, cognitive decline and incidence of dementia: A network meta-analysis. J Hypertens. 2013; 31: 1073-82
|
|
|
|
|
|
11）Gorelick PB, Scuteri A, Black SE, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011; 42: 2672-713
|
|
|
|
|
|
12）Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimerʼs disease and other disorders. Nat Rev Neurosci. 2011; 12: 723-38
|
|
|
|
|
|
13）Carnevale D, Mascio G, DʼAndrea I, et al. Hypertension induces brain beta-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension. 2012; 60: 188-97
|
|
|
|
|
|
14）Deane R, Du Yan S, Submamaryan RK, et al. Rage mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med. 2003; 9: 907-13
|
|
|
|
|
|
15）Kook SY, Hong HS, Moon M, et al. Abeta(1)(-)(4)(2)-rage interaction disrupts tight junctions of the blood-brain barrier via ca(2)(+)-calcineurin signaling. J Neurosci. 2012; 32: 8845-54
|
|
|
|
|
|
16）Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012; 122: 1377-92
|
|
|
|
|
|
17）Min LJ, Mogi M, Shudou M, et al. Peroxisome proliferator-activated receptor-gamma activation with angiotensin ii type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension. 2012; 59: 1079-88
|
|
|
|
|
|
18）Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010; 107: 7036-41
|
|
|
|
|
|
19）Yamazaki KG, Gonzalez E, Zambon AC. Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: role of the cardiac fibroblast. J Cardiovasc Transl Res. 2012; 5: 805-13
|
|
|
|
|
|
20）Hernandez C, Simo R. Neuroprotection in diabetic retinopathy. Curr Diab Rep. 2012; 12: 329-37
|
|
|
|
|
|
21）Ishibashi Y, Matsui T, Takeuchi M, et al. Beneficial effects of metformin and irbesartan on advanced glycation end products (ages)-rage-induced proximal tubular cell injury. Pharmacol Res. 2012; 65: 297-302
|
|
|
|
|
|
22）Kato T, Yamashita T, Sekiguchi A, et al. Angiotensin II type 1 receptor blocker attenuates diabetes-induced atrial structural remodeling. J Cardiol. 2011; 58: 131-6
|
|
|
|
|
23）Yamagishi S, Maeda S, Matsui T, et al. Role of advanced glycation end products (ages) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta. 2012; 1820: 663-71
|
|
|
|
|
|
24）Carnevale D, Mascio G, Ajmone-Cat MA, et al. Role of neuroinflammation in hypertension-induced brain amyloid pathology. Neurobiol Aging. 2012; 33: 205 e219-29
|
|
|
|
|
|
25）Hajjar I, Brown L, Mack WJ, et al. Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol. 2012; 69: 1632-8
|
|
|
|
|
|
26）Paris D, Bachmeier C, Patel N, et al. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med. 2011; 17: 149-62
|
|
|
|
|